Lord, Abbett & Co. LLC Chemo Centryx, Inc. Transaction History

Lord, Abbett & Co. LLC

$31.4 Billion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $1.4 Million - $3.27 Million	-63,133 Reduced 35.02%	117,152 $6.05 Million
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $2.77 Million - $4.96 Million	180,285 New	180,285 $4.47 Million
Q2 2021 Aug 11, 2021	SELL	$9.59 - $50.88 $5.43 Million - $28.8 Million	-565,911 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$49.53 - $68.4 $3.42 Million - $4.73 Million	69,147 Added 13.92%	565,911 $29 Million
Q4 2020 Feb 09, 2021	SELL	$47.25 - $65.16 $2.25 Million - $3.1 Million	-47,632 Reduced 8.75%	496,764 $30.8 Million
Q3 2020 Nov 12, 2020	BUY	$46.35 - $61.69 $1.29 Million - $1.72 Million	27,805 Added 5.38%	544,396 $29.8 Million
Q2 2020 Aug 14, 2020	SELL	$38.58 - $65.07 $6.51 Million - $11 Million	-168,678 Reduced 24.61%	516,591 $29.7 Million
Q1 2020 May 14, 2020	BUY	$32.73 - $50.78 $6.69 Million - $10.4 Million	204,316 Added 42.48%	685,269 $27.5 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $3.28 Million - $19 Million	480,953 New	480,953 $19 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.